Last updated 2026-07-20
Total raised
—
Stage
Pre-Funding
Founded
1985
Headcount
31
HQ
Rehovot, Israel
Sector
Health Tech & Life Sciences
About
Shulov Innovative Science Ltd. (SIS) is an advanced clinical-stage biopharmaceutical company focused on developing New Chemical Entities (NCE's) for a variety of therapeutic uses. These NCE's are short synthetic peptides, branded as ZEP-3 and ZEP-4, possessing unique pharmacological activity as anti-inflammatory, anti-viral, and analgesic agents. The company's technology is protected by multiple patents and originated from research into snake venom to find analgesic components. SIS is conducting clinical studies in Israel and planning for US trials for various indications including Atopic Dermatitis, Herpes Labialis, Herpes Zoster, Genital Herpes, Burns, Lung Inflammation, and Psoriasis.
Q&A
- What is SIS Shulov Innovative Science's primary focus?
- SIS Shulov Innovative Science is an advanced clinical-stage biopharmaceutical company focused on developing New Chemical Entities (NCEs) for various therapeutic uses, particularly in dermatology.
- What are the lead compounds under development by SIS Shulov Innovative Science?
- The company's lead compounds are short synthetic peptides branded as ZEP-3 and ZEP-4, which possess combined anti-inflammatory, anti-viral, and analgesic properties.
- What is the current clinical trial status for SIS Shulov Innovative Science's lead compound for Herpes Labialis?
- SIS Shulov Innovative Science has completed a Phase II clinical study in Herpes Labialis (cold sores) and is preparing for a pre-IND meeting with the FDA to secure an IND submission for an advanced Phase III clinical trial in the US.
- Is SIS Shulov Innovative Science conducting any other clinical studies?
- Yes, SIS Shulov Innovative Science is conducting a Phase II clinical study in Atopic Dermatitis (AD) across 9 clinical sites in Israel.
- What additional clinical indications is SIS Shulov Innovative Science developing?
- The company is developing additional clinical indications including Herpes Zoster, Genital Herpes, Burns, and Lung Inflammation, with pre-clinical work completed and readiness to start Phase I/II studies for each.
- When was SIS Shulov Innovative Science founded?
- SIS Shulov Innovative Science was founded in January 1985.
- How many employees does SIS Shulov Innovative Science have?
- SIS Shulov Innovative Science has 11-50 employees.
- Where is SIS Shulov Innovative Science headquartered?
- SIS Shulov Innovative Science is headquartered in Rehovot, Center District, Israel.
Team · 2
Prof. Aharon Shulov
Founder · Founder
Aviv Marx
Founder · Founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 PatentsVerified
Tags
pain-reliefskin-carebiopharmaceuticaltargeted-therapydermatologyanti-inflammatorytopical-treatment
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | sis-shulov.com |
|---|---|
| facebook.com/p/SIS-Shulov-Innovative-Science-100063781163571 |
Identifiers & details
| Legal name | Shulov Innovative Science Ltd. |
|---|---|
| Founded | 1985-1 |
| Employees (exact) | 31 |
Radar intelligence
Web history (Wayback)
| Domain | sis-shulov.com |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 511084519 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 1985-09-19 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 2 — violation (1), annual_report (1) |
| Registered address | אופנהיימר 10 רחובות |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-11 | עדכון הפרה |
| 2026-06-11 | דו~ח שנתי |